Also known as pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate and Xeloda.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
